Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by DaveAuon Feb 15, 2009 10:23am

388 Views

Post# 15780281

RE: RE: RE: RE: Cyclophosphamide study?

You guys seem to have missed the latest comments on this study (listen to recent CCs). I don't have time to look it up but this trial is likely to be terminated early as the company no longer feels it will tell them anything new since they already have data on immune suppression from the other chemo trials (eg. Harrington presentation).

The trial with the real blockbuster news potential is the lung trial. Its a first line trial, patients are pre-screened for REO susceptibility, and REO has already been shown to be particularly effective in lung. You can't overemphasize how big it would be if that trial shows strong results.

Bullboard Posts

Debt-free cannabis company set for next stage of growth